Sifalimumab

DB12773InvestigationalProtein Based Therapies

Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,... Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

Code names: MEDI-545

Resolves to

Compound

UNIIXOY1YA7RMCCAS1006877-41-3

Targets

P01563IFNA2

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

Which drugs share a target with Sifalimumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account